BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $4528.T readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06803823-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ONO-2020 readout (P2) · Ono Pharmaceutical Co.\, Ltd. $4528.T
DESCRIPTION:A Study of ONO-2020 in Patients With Agitation Associated With 
 Alzheimer's Disease Dementia\n\nPrimary completion date: 2026-12-31 (estim
 ated)\nPhase 2 · Neuro · Agitation Associated With Alzheimer's Disease D
 ementia\nEnrollment: 90 · Sites: 39\n\nPrimary completion = last particip
 ant's primary-endpoint data collected\; topline results usually follow wee
 ks to months later. Sponsor-reported\, often an estimate. Not investment a
 dvice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06803823\nhttps
 ://clinicaltrials.gov/study/NCT06803823
URL:https://datacutoff.com/radar.html?nct=NCT06803823
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06579573-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cenobamate readout (P3) · Ono Pharmaceutical Co.\, Ltd. $4528.T
DESCRIPTION:ONO-2017 Study Japanese Patients With Primary Generalized Tonic
  Clonic Seizures.\n\nPrimary completion date: 2027-01-31 (estimated)\nPhas
 e 3 · Neuro · Epilepsy\, Generalized\nEnrollment: 15 · Sites: 25\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT06579573\nhttps://clinicaltrials.gov/study/NCT06579573
URL:https://datacutoff.com/radar.html?nct=NCT06579573
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590896-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cenobamate readout (P2) · Ono Pharmaceutical Co.\, Ltd. $4528.T
DESCRIPTION:Safety of Cenobamate in Japanese Subjects With Partial Onset Se
 izures\n\nPrimary completion date: 2027-01-31 (estimated)\nPhase 2 · Neur
 o · Epilepsies\, Partial\nEnrollment: 100 · Sites: 29\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct
 =NCT06590896\nhttps://clinicaltrials.gov/study/NCT06590896
URL:https://datacutoff.com/radar.html?nct=NCT06590896
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696716-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ONO-4059 readout (P3) · Ono Pharmaceutical Co.\, Ltd. $4528.T
DESCRIPTION:ONO-4059 Study in Patients With Steroid-resistant Pemphigus\n\n
 Primary completion date: 2027-09-30 (estimated)\nPhase 3 · Immuno · Pemp
 higus\, Steroid-resistant Pemphigus\nEnrollment: 34 · Sites: 25\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT06696716\nhttps://clinicaltrials.gov/study/NCT06696716
URL:https://datacutoff.com/radar.html?nct=NCT06696716
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
